SCHEMBL3074478

SCHEMBL3074478

Cn1cc(-c2cnc3ccc(-c4cncc(NS(=O)(=O)c5cccc(Cl)c5Cl)c4)cc3n2)cn1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR3 P22607 7/20 0.48
KDR P35968 7/20 0.48
SGK1 O00141 5/20 0.44
ALPL P05186 2/20 0.43
CYP3A4 P08684 1/20 0.42
SGK3 Q96BR1 1/20 0.42
SGK2 Q9HBY8 1/20 0.42
FGFR1 P11362 4/20 0.42
FGFR2 P21802 4/20 0.42
FGFR4 P22455 3/20 0.42
MET P08581 1/20 0.41
PRF1 P14222 2/20 0.41
CSF1R P07333 1/20 0.41
FLT3 P36888 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
THRB P10828 1/20 0.40
HPGD P15428 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3095876 0.93 FGFR3 (0.50) FGFR3KDRSGK1ALPLFGFR1
SCHEMBL3088643 0.88 FGFR3 (0.48) FGFR3KDRALPLFGFR1FGFR2
SCHEMBL3093314 0.87 FGFR3 (0.57) FGFR3KDRSGK1ALPLMET
SCHEMBL3096942 0.87 FGFR3 (0.46) FGFR3KDRALPLFGFR1FGFR2
SCHEMBL3084748 0.86 PIK3CA (0.53) FGFR3KDRSGK1ALPLFGFR1
SCHEMBL3092923 0.86 FGFR3 (0.48) FGFR3KDRSGK1ALPLFGFR1
SCHEMBL3074232 0.86 FGFR3 (0.54) FGFR3KDRALPLFGFR1FGFR2
SCHEMBL3080314 0.85 ALPL (0.54) FGFR3KDRALPLFGFR1FGFR2
SCHEMBL3091968 0.85 HSPD1 (0.43) FGFR3KDRALPLFGFR1FGFR2
SCHEMBL3096681 0.84 FGFR3 (0.57) FGFR3KDRALPLFGFR1FGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100234386-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-09-16 US disclosed
US-20100234386-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-09-16 US disclosed
US-20100234386-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2010-09-16 US disclosed
US-7592342-B2 Quinoxaline derivatives as PI3 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-09-22 US disclosed
US-7592342-B2 Quinoxaline derivatives as PI3 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-09-22 US disclosed
US-7592342-B2 Quinoxaline derivatives as PI3 kinase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-09-22 US disclosed
US-20080293706-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2008-11-27 US disclosed
US-20080293706-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2008-11-27 US disclosed
US-20080293706-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS GLAXOSMITHKLINE LLC 2008-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293706-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS PIP5K1A, PIK3CB, PIK3CG FGFR3 2690/4885KDR 1697/4885SGK1 1217/4885
US-20100234386-A1 QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS PIP5K1A, PIK3CB, PIK3CG FGFR3 2690/4885KDR 1697/4885SGK1 1217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.